NCT01722331View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

PHASE3CompletedINTERVENTIONAL

Enrollment

772

Participants

Timeline

Start Date

December 6, 2012

Primary Completion Date

October 28, 2015

Study Completion Date

November 10, 2021

Conditions

Plaque Psoriasis

Interventions

DRUG

Tildrakizumab 200 mg

Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)

DRUG

Tildrakizumab 100 mg

Tildrakizumab 100 mg/mL PFS

DRUG

Matching Placebo

Matching placebo to tildrakizumab PFS

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT01722331 - A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) | Biotech Hunter | Biotech Hunter